49. Systemic lupus erythematosus Clinical trials / Disease details
Clinical trials : 946 / Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2006-002107-13-IT (EUCTR) | 24/11/2006 | 09/03/2007 | A randomized, multicenter, open-label, 6-month study to explore the efficacy and safety of enteric-coated mycophenolate sodium myfortic in combination with two corticosteroid regimens for the treatment of lupus nephritis flare - ND | A randomized, multicenter, open-label, 6-month study to explore the efficacy and safety of enteric-coated mycophenolate sodium myfortic in combination with two corticosteroid regimens for the treatment of lupus nephritis flare - ND | Systemic lupus erythematosis MedDRA version: 9.1;Level: LLT;Classification code 10042945;Term: Systemic lupus erythematosus | Trade Name: MYFORTIC*50CPR RIV 360MG INN or Proposed INN: Mycophenolic acid Trade Name: DELTACORTENE*20CPR 5MG INN or Proposed INN: Prednisone Trade Name: MYFORTIC*50CPR RIV 360MG INN or Proposed INN: Mycophenolic acid Trade Name: DELTACORTENE*20CPR 5MG INN or Proposed INN: Prednisone | NOVARTIS FARMA | NULL | Not Recruiting | Female: yes Male: yes | 80 | Hungary;Germany;United Kingdom;France;Spain;Italy;Greece |